Although ERBB2 gene amplification and SCLC transformation have been reported as AR mechanisms against EGFR-TKIs in clinical settings, as far as we know, no cell line model has been developed with either ERBB2 gene amplification or SCLC transformation by using chronic exposure to EGFR-TKIs. This evidence concerns the gene AR and small cell lung carcinoma.